CTLA4 and gastric cancer: The phase II INFINITY trial investigated the activity and safety of the combination of tremelimumab (anti-CTLA4) and durvalumab (anti-PDL1) as a neoadjuvant (Cohort 1) or definitive (Cohort 2) treatment for dMMR/MSI-H and EBV-negative locally advanced esophagogastric junction/gastric cancer patients (≥cT2 or N+) [42].